01Structure
Microfat retains architecture
Small adipose lobules are prepared as gently as possible for a structural task.
Microfat and Nanofat · Istanbul
Microfat and Nanofat · Istanbul
Microfat and Nanofat
Microfat and nanofat begin with adipose-tissue collection but become different preparations. Microfat aims to retain small fat lobules for structural use; nanofat is emulsified and filtered into a more fluid, heterogeneous tissue product.
Autologous means patient-derived, not standardised or risk-free. Donor area, processing route, final tissue structure, target layer and clinical purpose must be named before either preparation is considered.
Quick Orientation
Four distinctions before treatment
The processing route shows which adipose-tissue product actually exists.
Terminology is not globally uniform, so the harvest, processing steps, retained structure and intended function must be documented.
02Process
Nanofat changes architecture
Further mechanical passage and filtration create a finer material with limited predictable volume function.
03Boundary
SVF is a separate product
Nanofat, isolated SVF and culture-expanded cells are not materially interchangeable.
04Evidence
Hair evidence stays separate
Skin-texture or volume findings do not establish a scalp or hair outcome.
Two Adipose-Tissue Preparations
Architecture · processing · clinical task
Microfat is a small-particle fat graft; nanofat is mechanically altered tissue.
Microfat aims to preserve viable adipose compartments. In classically emulsified and filtered nanofat, mature adipocytes largely lose structural integrity while matrix and stromal components remain variable.
What may be assessed
- Consider microfat for a clearly limited structural task
- Assess nanofat for a selected superficial tissue purpose
- Document donor area, processing, target layer and transferred volume
- Review donor healing and the clinical endpoint separately
What cannot be assumed
- Describe nanofat as a purified or dosed stem-cell treatment
- Equate microfat, nanofat, SVF or culture-expanded cells
- Use skin findings as proof of hair growth
- Guarantee graft survival, tissue renewal or new hair
Particle size alone does not define the product. Preserved architecture, actual processing, composition, intended function and local framework all matter.
Medical Suitability
Indication · donor area · anatomy · product
Five checks come before adipose harvest or transfer.
Personal examination connects the clinical target, donor reserve, procedure risk, intended preparation and a measurable endpoint.
- 01
Define the target
Volume loss, skin change, scar or hair question is assessed separately with its alternatives.
- 02
Review procedure suitability
Health, medicines, bleeding, infection, healing, anaesthetic and previous procedures are considered.
- 03
Examine the donor area
Adipose distribution, skin, scars and a defensible collection volume are assessed.
- 04
Select product and layer
Microfat or nanofat, processing, volume, cannula, target plane and vascular anatomy are documented.
- 05
Check status and endpoint
Current local requirements, baseline images, review timing and stopping rules are established.
Harvest, Processing and Transfer
One source · two product routes
Every processing step changes the final tissue preparation.
Harvest cannula, pressure, fluid, cleaning, fragmentation, filtration, standing time and transfer system influence structure and contamination risk.
01Harvest
Collect a limited lipoaspirate
A defined adipose volume is collected under an appropriate marking, anaesthetic and sterility plan.
- Record donor site and amount
- Document cannula, pressure and fluid
- Review bleeding, wound and contour
02Microfat
Preserve transplantable structure
Cleaning and size adjustment aim to retain small viable lobules for the intended anatomical space.
- Separate oil, blood and fluid
- Match particle size to delivery route
- Record volume by target area
03Nanofat
Emulsify and filter tissue
Repeated mechanical passage creates a more fluid preparation without dependable structural volume.
- Record every processing step
- Describe final structure and route
- Do not claim an unmeasured cell dose
A closed device does not remove every risk. Processing time, sterility, patient identification and complete traceability remain part of the product.
Evidence and Limits
Laboratory differences · small clinical cohorts
Microfat, nanofat, skin and hair studies answer different questions.
Laboratory studies confirm structural differences between preparations. Clinical literature is heterogeneous and often uses small groups, mixed products or non-hair endpoints.
Classic nanofat loses adipocytes
The original description found no viable mature adipocytes after emulsification, while stromal material remained.
Direct comparison shows difference
Histology and viable-cell counts differ between microfat, nanofat and further concentrated products.
Skin literature stays local
Texture, scar or fine-line reports cannot be transferred to the scalp as evidence of hair growth.
Hair evidence is preliminary
Small uncontrolled reports do not establish a routine product, schedule or durable result.
A finding for microfat, classic nanofat, concentrated nanofat or isolated cells cannot be transferred to another preparation.
Individual Tissue Plan
No standard package
Harvest needs a justified tissue task and a measurable endpoint.
Adipose collection is not treated as a minor preparation step. Its burden must be justified by a clear, anatomically limited aim.
Name the tissue task
Structural volume, superficial tissue change and a research-stage hair question are not merged.
Limit the harvest
Donor site, amount, anaesthetic, scar and contour risks are weighed against the clinical aim.
Document one product route
Processing, target layer, volume, instruments and safety boundaries are specified.
Agree the review point
Donor healing, target area and the selected endpoint are assessed separately before any new decision.
Healing and Follow-Up
Two regions · different timelines
Early fullness is often swelling, not proof of graft survival or effect.
Donor and target areas heal differently. Structural volume, tissue findings and any hair endpoint are therefore reviewed later and separately.
- 01Early
First days
Tenderness, swelling, bruising, small entry wounds and fluid leakage may affect both areas.
- 02Healing
Following weeks
Wound healing, infection, firmness, contour and persistent pain are assessed.
- 03Endpoint
Following months
Microfat volume and tissue findings are reviewed after swelling; hair requires its own longer comparison.
- 04Decision
Later balance
Resorption, asymmetry, nodules, burden and benefit inform observation, correction or no further procedure.
Risks and Alternatives
Autologous tissue is not risk-free
Harvest, processing and transfer have distinct complication pathways.
Consent includes common local effects, donor-site problems, variable graft behaviour and uncommon but serious delivery-related harm.
01Harvest
Donor area
Pain, bruising, bleeding, infection, fluid collection, scarring, altered sensation or contour change may occur.
02Transfer
Target area
Swelling, infection, nodules, cysts, fat necrosis, asymmetry and unpredictable resorption are possible.
03Decision
Vascular and other options
Intravascular fat delivery can cause severe harm; a less invasive option or no procedure may be safer.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Unexpected or worsening symptoms after harvest or transfer require prompt in-person assessment; remote review cannot establish tissue or vascular findings.
Istanbul and Follow-Up
Travel around two treated regions
Microfat or nanofat requires time for donor and target care.
Travel planning connects personal examination, possible harvest, early checks and a reliable route to local assessment after return.
01Before travel
Organise existing records
Medicines, earlier procedures, allergies and relevant clinical information frame the examination.
02Bağdat Caddesi
Examine both regions
Target, donor reserve, scars, anatomy, alternatives, status and travel burden are reviewed.
03Procedure
Keep the procedure conditional
Only after suitability would harvest, documented processing, transfer and early review be considered.
04After return
Plan return care
Wound care, activity, warning signs, local assessment access and review timing are agreed.
The Doctor Aslan Approach
Transparency before regenerative language
Harvest, final tissue, delivery layer and clinical purpose guide the decision.
The two preparations share an adipose source without sharing the same function. A responsible assessment may conclude that the tissue procedure is not justified.
Indication first
Volume, tissue, scar or hair questions are named and compared with less invasive options.
Show the tissue pathway
Donor, collection, cleaning, microfat or nanofat steps, layer and volume remain traceable.
Limit cell terminology
Nanofat is not presented as a pure cell fraction or a dosed stem-cell treatment.
Use endpoints, not promises
Healing, structural behaviour and any clinical outcome receive separate review times.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about microfat and nanofat; no personal diagnosis or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Microfat and Nanofat?+
Microfat and Nanofat is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Microfat and Nanofat?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Assess both regions · define the tissue product